2020 Strategic Imperatives in Competitive Intelligence

Maintaining CI’s 20/20 focus during a pandemic year

Dr. Mark Little

Senior Vice President, Prescient Intelligence & Insight

The second annual white paper on the strategic imperatives in CI is out now.

Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are developing a new drug or are already an established presence in the market. Alongside R&D, CI is crucial to businesses that want to maximize the value of their science.

In 2019, Prescient launched a study regarding the challenges within CI and the appropriate objectives, strategies and outcomes for CI professionals to address these. Speaking to key players in CI from across the pharmaceutical industry – from the big players to the most exciting disruptors – Prescient has widened the pool of interviewees for 2020 in order to gather even greater insights into the trends and challenges faced by CI professionals today.

Download this white paper to learn:

  • The top ten challenges for CI professionals in 2020
  • How the landscape has changed since our previous survey in 2019
  • Strategies and actions to address these challenges, along with Prescient’s recommendations

The 2020 Strategic Imperatives in Competitive Intelligence white paper is your unmissable guide to the issues that will shape CI in the pharmaceutical industry as we move into 2021 – download your free copy by submitting the form.

RELATED CONTENT